The EFfect of FinErenone in Kidney TransplantiOn Recipients: The EFFEKTOR Study
NCT06059664
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
EFFEKTOR is a vanguard, multicenter, phase 2 randomized, double blinded, placebo controlled clinical trial to determine the feasibility, tolerability, safety, and efficacy of finerenone in kidney transplant recipients (KTRs).
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Kidney Transplant; Complications
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- University of North Carolina, Chapel Hill
- Last updated on ClinicalTrials.gov
- April 14, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
North Carolina · 1
- UNC Eastowne Kidney Transplant Clinic · Chapel Hill, NC
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.